Nabilone for Agitation Blinded Intervention Trial (NAB-IT)

Agitation is common in patients with Alzheimer's Disease (AD) and is one of the most distressing and symptoms of AD. Agitation is associated with faster loss of independent living, increased caregiver stress, poorer quality of life, and increased risk of death. In addition, current treatments show only mild benefits but come with side effects. Therefore, identifying safer and more effective treatments for agitation in AD is a priority.

This study will look at whether nabilone is an effective treatment for agitation in AD patients. Nabilone is a manufactured cannabinoid (a medication based on one substance in cannabis) that is Health Canada approved. It is used to treat nausea and vomiting in cancer patients.

Participants in this study will receive either nabilone or a placebo for 8 weeks. The researchers will for improvement in agitation. They will also look for improvement in mental health symptoms, caregiver stress, memory and thinking, nutritional status, and pain.

null

Study Sponsored By

Sunnybrook Health Sciences Centre

Participants Required

More Information

Study ID: NCT04516057